With ‘Rapid Antigen Test’ having only taken several days to likely be one of the most commonly used words of 2022, everyone is looking for them but demand is monumentally outweighing supply. With their surge in use, it may only be a matter of time until Australian regulators fast-track approval of more RAT manufacturers with
Read More
Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs). The announcement represents significant market expansion, with Unitaid committing
Read More
Medtech company Atomo Diagnostics (ASX: AT1) has been granted regulatory approval in Australia for their patented AtomoRapid HIV (1&2) rapid diagnostic kit which will enable testing for HIV with just one drop of blood. The approval granted by the Therapeutic Goods Association (TAG) enables Atomo to commence distribution of the diagnostic test to medical professionals
Read More
Australians will soon have access to a rapid COVID-19 test where results can be obtained in just 15 minutes from a drop of blood following approval from the Therapeutic Goods Association (TGA) for Atomo Diagnostics’ (ASX: AT1) rapid antibody test. The test device has been independently tested at laboratories in France where the AtomoRapid test
Read More
With only one company set to list this month, it appears that the volatility that surrounds the ASX is prompting some companies to delay listing until some degree of normality in financial markets is restored. One company brave enough to face the current environment is Atomo Diagnostics Limited (Proposed ASX: AT1). The Sydney-based medical diagnostics
Read More